Bioxytran (BIXT) Interest Coverage Ratio Growth (1y) (2011 - 2026)
Bioxytran (BIXT) Interest Coverage Ratio Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -143.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -227.23% |
| Dec 31, 2025 | -242.20% |
| Sep 30, 2025 | 30.00% |
| Jun 30, 2025 | 75.90% |
| Mar 31, 2025 | -247.05% |
| Dec 31, 2024 | -149.70% |
| Sep 30, 2024 | 4.12% |
| Jun 30, 2024 | -15.26% |
| Mar 31, 2024 | 46.62% |
| Dec 31, 2023 | -58.95% |
| Sep 30, 2023 | -26,932.54% |
| Jun 30, 2023 | -213.00% |
| Mar 31, 2023 | 43.30% |
| Dec 31, 2022 | 4,722.24% |
| Sep 30, 2022 | 100.45% |
| Jun 30, 2022 | 30.84% |
| Mar 31, 2022 | 18.53% |
| Dec 31, 2021 | 93.69% |
| Sep 30, 2021 | -1,174.99% |
| Jun 30, 2021 | -8,088.70% |